Home Cart Sign in  
Chemical Structure| 934526-89-3 Chemical Structure| 934526-89-3

Structure of Pilaralisib
CAS No.: 934526-89-3

Chemical Structure| 934526-89-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL147 is a potent, orally bioavailable inhibitor of the class I PI3K family of lipid kinases with IC50 values of 39 nM/383 nM/36 nM/23 nM for PI3Kα/β/δ/γ, respectively and less potent to PI3Kβ.

Synonyms: XL147

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pilaralisib

CAS No. :934526-89-3
Formula : C25H25ClN6O4S
M.W : 541.02
SMILES Code : ClC1=C(C=C(C=C1)OC)NC2=NC3=CC=CC=C3N=C2NS(C4=CC(NC(C(C)(C)N)=O)=CC=C4)(=O)=O
Synonyms :
XL147
MDL No. :MFCD26142605
InChI Key :QINPEPAQOBZPOF-UHFFFAOYSA-N
Pubchem ID :56599306

Safety of Pilaralisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pilaralisib

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HR6 6 µM 5 days XL147 + trastuzumab inhibited proliferation and growth of HR6 cells Cancer Res. 2013 Feb 1;73(3):1190-200.
HR5 6 µM 5 days XL147 + trastuzumab inhibited proliferation and growth of HR5 cells Cancer Res. 2013 Feb 1;73(3):1190-200.
SUM190 6 µM 24 hours XL147 + trastuzumab inhibited proliferation and growth of SUM190 cells Cancer Res. 2013 Feb 1;73(3):1190-200.
HCC1569 6 µM 24 hours XL147 + trastuzumab inhibited proliferation and growth of HCC1569 cells Cancer Res. 2013 Feb 1;73(3):1190-200.
HCC1954 10 µM 24 hours XL147 + trastuzumab inhibited proliferation and growth of HCC1954 cells Cancer Res. 2013 Feb 1;73(3):1190-200.
CFBE41o− cells 3 µM 24 hours To evaluate the rescue effect of XL147 on ΔF508-CFTR function, results showed that XL147 partially restored ΔF508-CFTR function. CPT Pharmacometrics Syst Pharmacol. 2022 Feb;11(2):240-251.
PyVmT cells 25 nM 24, 48, 72 hours Evaluate the effect of XL147 on metabolic heterogeneity in PyVmT cells, results showed XL147 significantly reduced OMI index and metabolic heterogeneity Neoplasia. 2019 Jun;21(6):615-626.
HR6 cells 10 nM 24, 48, 72 hours Evaluate the drug response of XL147 on HR6 cells, showing a significant decrease in OMI index at 24 and 48 hours, but no significant change at 72 hours. Biomed Opt Express. 2017 Feb 28;8(3):1911-1925.
BT474 cells 10 nM 24, 48, 72 hours Evaluate the drug response of XL147 on BT474 cells, showing a significant decrease in OMI index at all time points. Biomed Opt Express. 2017 Feb 28;8(3):1911-1925.
MCF10A cells 1 µM 3 hours To evaluate the inhibitory effect of Pilaralisib on HER2T798M mutant cells. Results showed that Pilaralisib could inhibit the growth and signaling of HER2T798M mutant cells. Clin Cancer Res. 2013 Oct 1;19(19):5390-401.
BT474 cells 1 µM 3 hours To evaluate the inhibitory effect of Pilaralisib on HER2T798M mutant cells. Results showed that Pilaralisib could inhibit the growth and signaling of HER2T798M mutant cells. Clin Cancer Res. 2013 Oct 1;19(19):5390-401.
MDA453 cells 6 µM 48 hours Measure HER3 mRNA levels, found significant increase after XL147 treatment Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23.
SKBR3 cells 6 µM 48 hours Measure HER3 mRNA levels, found significant increase after XL147 treatment Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23.
BT474 cells 6 µM 6 hours Measure HER3 mRNA levels, found significant increase after XL147 treatment Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic female mice HR6 xenografts Orally 100 mg/kg XL147 daily, trastuzumab twice weekly, for 28 days XL147 + trastuzumab significantly inhibited the growth of HR6 xenografts Cancer Res. 2013 Feb 1;73(3):1190-200.
Nude mice BT474T798M xenograft model Oral gavage 100 mg/kg Once daily for 4-5 weeks To evaluate the inhibitory effect of Pilaralisib on HER2T798M mutant tumors in vivo. Results showed that Pilaralisib could significantly inhibit tumor growth. Clin Cancer Res. 2013 Oct 1;19(19):5390-401.
Mice Gastrointestinal stromal tumor model Oral gavage 100 mg/kg Once daily for 7 days To evaluate the therapeutic effect of Pilaralisib on gastrointestinal stromal tumors, results showed inhibition of PI3K signaling pathway and reduced tumor cell proliferation. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8448-E8457
NIH Swiss mice Lung squamous cell carcinoma model Oral gavage 100 mg/kg 5 days a week for 4 weeks To study the therapeutic effect of XL-147 on lung squamous cell carcinoma and the potential of exosomal miRNAs as pharmacodynamic biomarkers Cancers (Basel). 2019 Apr 4;11(4):477
FVB mice PyVmT breast cancer model Oral gavage 50 mg/kg Once daily for 14 days Evaluate the effect of XL147 on tumor growth and metabolic heterogeneity in PyVmT tumors, results showed XL147 combined with paclitaxel significantly reduced tumor growth and metabolic heterogeneity Neoplasia. 2019 Jun;21(6):615-626.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.18mL

9.24mL

1.85mL

0.92mL

18.48mL

3.70mL

1.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories